![](/img/cover-not-exists.png)
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
Jill Gilbert, Michael A. Carducci, Sharyn D. Baker, Elizabeth C. Dees, Ross DonehowerVolume:
24
Language:
english
Pages:
10
DOI:
10.1007/s10637-006-8219-0
Date:
November, 2006
File:
PDF, 287 KB
english, 2006